US2015374668A1PendingUtilityA1

Chemical compounds

56
Assignee: JANSSEN PHARMACEUTICALS INCPriority: Sep 4, 2009Filed: Sep 9, 2015Published: Dec 31, 2015
Est. expirySep 4, 2029(~3.1 yrs left)· nominal 20-yr term from priority
Inventors:Pingyun ChenRicky CouchMaosheng DuanBeth Adams Norton
A61P 31/14A61P 31/00A61P 31/12C07D 487/20C07D 491/113C07D 491/10A61K 31/7056C07D 403/12C07D 519/00A61K 31/435A61K 31/4178C07D 491/107C07D 487/10C07D 495/10A61K 38/21C07D 403/14C07D 471/10A61K 31/407
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are compounds of Formula III. Also disclosed are salts of the compounds, pharmaceutical composition comprising the compounds or salts, and methods for treating HCV infection by administration of the compounds or salts.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for treating an HCV viral infection in a human comprising administration the compound 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, and the administration of at least one other antiviral agent. 
     
     
         2 . The method of  claim 1  wherein the depicted compound is enantiomerically enriched with the following enantiomer 
       
         
           
           
               
               
           
         
       
     
     
         3 . The method of  claim 1  wherein said salt is either a di-HCl salt or a sulfate salt. 
     
     
         4 . The method of  claim 1  wherein said salt is a sulfate salt. 
     
     
         5 . The method of  claim 2  wherein said salt is either a di-HCl salt or a sulfate salt. 
     
     
         6 . The method of  claim 2  wherein said salt is a sulfate salt.

Join the waitlist — get patent alerts

Track US2015374668A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.